American Cancer Society recommends regular prostate cancer testing in updated guidelines
American Cancer Society updates prostate cancer screening guidelines with new age-based PSA testing recommendations.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The American Cancer Society has released updated prostate cancer screening guidelines that establish specific age thresholds for prostate-specific antigen (PSA) testing. According to coverage from Medical Daily, the new recommendations call for PSA tests every two years starting at age 50 for the general male population, while Black men should begin yearly testing at age 45. The guidelines represent a shift from previous recommendations and aim to address disparities in prostate cancer outcomes. Coverage from People.com frames the update as a move to save lives through earlier detection, while Cleveland.com emphasizes what men should know about the changed advice. WJBF provides a breakdown of what men need to know following the major guideline update.
The coverage emphasizes the racial disparity component of the updated guidelines, with Medical Daily specifically highlighting the earlier and more frequent testing schedule recommended for Black men. People.com focuses on the life-saving potential of the new screening protocol, while Cleveland.com takes a practical approach by explaining what men should know about the changes. WJBF similarly provides actionable information for men navigating the updated recommendations. The simultaneous publication across these outlets — spanning national lifestyle media, regional news, medical publications, and local Cleveland coverage — suggests the American Cancer Society distributed the guidelines broadly to reach diverse audiences. The outlets collectively cover the key actionable details: the specific ages, testing frequencies, and the differentiated schedule based on race.
Prostate cancer screening has long been a subject of debate in the medical community, with previous guidelines from various organizations differing on the appropriate age to begin PSA testing and how frequently it should occur. The PSA test measures prostate-specific antigen levels in the blood, which can be elevated due to cancer but also due to benign conditions, leading to concerns about overdiagnosis and overtreatment. The American Cancer Society's previous guidelines had emphasized shared decision-making between patients and doctors rather than specific age-based recommendations. This update appears to move toward more prescriptive guidance, particularly with the explicit differentiation for Black men, who face higher incidence rates and mortality from prostate cancer. The guidelines' focus on addressing racial disparities aligns with broader public health efforts to reduce inequities in cancer outcomes.
Going forward, coverage indicates that implementation and adoption of these guidelines by healthcare providers will be the key development to watch. The articles suggest men should discuss the new recommendations with their healthcare providers to determine individual screening plans. Medical community response, including whether other major organizations such as the U.S. Preventive Services Task Force or the American Urological Association align with or diverge from these updated recommendations, will shape clinical practice. Insurance coverage decisions for the more frequent testing schedule, particularly for Black men starting at 45, may also affect real-world adoption. The American Cancer Society's influence on clinical practice means these guidelines could shift screening patterns nationwide, though the coverage does not specify whether the Society has changed its stance on shared decision-making alongside the new age-based thresholds.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (95% supported) Updated 2d ago.
Quick answers
What are the new PSA testing ages and frequencies?
The American Cancer Society now recommends PSA tests every two years starting at age 50 for most men, and yearly testing starting at age 45 for Black men.
Why does the guideline differentiate by race?
Black men face higher incidence rates and mortality from prostate cancer, prompting earlier and more frequent screening recommendations to address this disparity.
Do these guidelines replace shared decision-making with doctors?
Coverage does not specify whether the American Cancer Society has changed its stance on shared decision-making alongside the new age-based thresholds.
Coverage (4)
- American Cancer Society Reveals New Prostate Cancer Screening Guidelines to Save Lives People.com · 3d ago
- What men need to know after a major update to prostate cancer guidelines WJBF · 3d ago
- American Cancer Society Backs PSA Tests Every Two Years at 50 and Yearly at 45 for Black Men Medical Daily · 3d ago
- Prostate cancer screening advice just changed. Here’s what men should know Cleveland.com · 3d ago
Topics
Related trends
Iowa ranks No. 2 for young adult cancer cases
Iowa ranks second nationally for young adult cancer cases as new research links rising rates to early detection of prostate and breast cancers while death rates decline.
New prostate cancer screening guidelines include regular testing for most older men
The American Cancer Society now recommends routine PSA blood tests every two years for men ages 50 to 69, with annual screening starting at 45 for Black men and those with a strong family history.
A ‘clear recommendation’ for men: Get screened for prostate cancer
The American Cancer Society now recommends regular PSA blood tests for prostate cancer screening, reversing its 2010 guidance that emphasized shared decision-making.
What Happens to Your Bones When You Take Vitamin D With Calcium
Taking vitamin D with calcium affects bone health, but expert guidance warns that excessive intake carries serious risks.
Domain-alteration chimeras rewire oncogenic complexes in prostate cancer
University of Michigan researchers developed DALTAC-1, a bifunctional small molecule that glues the androgen receptor and p300/CBP together in an abnormal configuration, suppressing prostate tumor growth in preclinical models with roughly 1,000-fold greater potency than separate
Strong immune system can prevent prostate cancer, Oxford study finds
An Oxford study links stronger immune activity to lower prostate cancer risk, drawing coverage across research, health and mainstream outlets.